Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.983,549,DB00428,Streptozocin
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],1.35,550,DB00428,Streptozocin
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.998,551,DB00428,Streptozocin
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],1.36,552,DB00428,Streptozocin
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.164,553,DB00428,Streptozocin
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.0846,554,DB00428,Streptozocin
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.205,555,DB00428,Streptozocin
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.0967,556,DB00428,Streptozocin
,8799497,bioavailability,The bioavailability of insulin estimated from the hypoglycemic effect was about 2% in the presence of either protease inhibitor.,Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799497/),%,2,14039,DB00428,Streptozocin
,150943,half-life (T 0.5),The half-life (T 0.5) for the plasma disappearance of intact drug was 5 minutes.,Pharmacologic disposition of chlorozotocin in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/150943/),min,5,16376,DB00428,Streptozocin
,150943,T 0.5,The plasma disappearance of the ethyl-14C group was biphasic up to 120 minutes after administration; the T 0.5 of the initial phase was 17.5 minutes and the T 0.5 of the prolonged second phase was107 minutes.,Pharmacologic disposition of chlorozotocin in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/150943/),min,17.5,16377,DB00428,Streptozocin
,150943,T 0.5,The plasma disappearance of the ethyl-14C group was biphasic up to 120 minutes after administration; the T 0.5 of the initial phase was 17.5 minutes and the T 0.5 of the prolonged second phase was107 minutes.,Pharmacologic disposition of chlorozotocin in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/150943/),min,107,16378,DB00428,Streptozocin
,150943,Uptake,Uptake into the bone marrow at 60 minutes after ip administration of the ethyl-labeled drug was 6.6 pmols of the ethyl-14C group covalently bound to proteins and nucleic acids per 10(7) nucleated cells.,Pharmacologic disposition of chlorozotocin in mice. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/150943/),pM,6.6,16379,DB00428,Streptozocin
,22659626,k(a),"Exenatide exhibited rapid absorption with k(a)=4.45 h(-1), and the two-compartment model well described its pharmacokinetic profile.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),1/[h],4.45,16437,DB00428,Streptozocin
,22659626,S(m1),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.822,16438,DB00428,Streptozocin
,22659626,SC(50),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),[μg] / [l],4.02,16439,DB00428,Streptozocin
,22659626,S(m2),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0513,16440,DB00428,Streptozocin
,22659626,I(m),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0381,16441,DB00428,Streptozocin
,2935437,plasma half-life,"After intravenous injection of [14C]-1,5AG, its plasma half-life was determined to be between 120 and 180 min.","Marked depletion of plasma 1,5-anhydroglucitol, a major polyol, in streptozocin-induced diabetes in rats and the effect of insulin treatment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935437/),min,120 and 180,20053,DB00428,Streptozocin
,28578255,limit of detection (LOD),"The limit of detection (LOD) and limit of quantification (LOQ) values of SR1001 were 1 and 5ng/mL, respectively.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),[ng] / [ml],1,28330,DB00428,Streptozocin
,28578255,limit of quantification (LOQ),"The limit of detection (LOD) and limit of quantification (LOQ) values of SR1001 were 1 and 5ng/mL, respectively.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),[ng] / [ml],5,28331,DB00428,Streptozocin
≥,28578255,extraction recoveries,"The extraction recoveries of SR1001 were ≥80%, and no significant matrix effect was observed.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),%,80,28332,DB00428,Streptozocin
,28578255,elimination half-lives,"The SR1001 drug concentration-time curves for organs and plasma showed similar trends, and the elimination half-lives of SR1001 in diabetic mice were about 12h.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),h,12,28333,DB00428,Streptozocin
,28578255,maximum concentration (Cmax,"SR1001 was highly bound to plasma protein, resulting in a much higher maximum concentration (Cmax=144394ng/mL) and area under the concentration-time curve (AUC0-t=2728258ng/mL*h), but a low tissue/plasma partition coefficient (Kp) value of <0.3.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),[ng] / [ml],144394,28334,DB00428,Streptozocin
,28578255,area under the concentration-time curve (AUC0-t,"SR1001 was highly bound to plasma protein, resulting in a much higher maximum concentration (Cmax=144394ng/mL) and area under the concentration-time curve (AUC0-t=2728258ng/mL*h), but a low tissue/plasma partition coefficient (Kp) value of <0.3.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),[ng] / [h·ml],2728258,28335,DB00428,Streptozocin
<,28578255,tissue/plasma partition coefficient (Kp),"SR1001 was highly bound to plasma protein, resulting in a much higher maximum concentration (Cmax=144394ng/mL) and area under the concentration-time curve (AUC0-t=2728258ng/mL*h), but a low tissue/plasma partition coefficient (Kp) value of <0.3.","Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578255/),,0.3,28336,DB00428,Streptozocin
,28808833,PDI,The prepared NCs has mean particle size 677.5 ± 72.5 nm and PDI 0.152 ± 0.061.,Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28808833/),,0.152,41905,DB00428,Streptozocin
,19009515,unbound fraction,The drug exhibits high binding characteristics to serum protein (unbound fraction: 0.01).,Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),,0.01,60881,DB00428,Streptozocin
,19009515,unbound fraction,The unbound fraction of NFV in diabetic rats (0.04) was greater than that in the control (0.015).,Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),,0.04,60882,DB00428,Streptozocin
,19009515,unbound fraction,The unbound fraction of NFV in diabetic rats (0.04) was greater than that in the control (0.015).,Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),,0.015,60883,DB00428,Streptozocin
,19009515,AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],1.75,60884,DB00428,Streptozocin
,19009515,AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],1.36,60885,DB00428,Streptozocin
,19009515,AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],1.69,60886,DB00428,Streptozocin
,19009515,AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],1.19,60887,DB00428,Streptozocin
,19009515,unbound AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],0.026,60888,DB00428,Streptozocin
,19009515,unbound AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],0.054,60889,DB00428,Streptozocin
,19009515,unbound AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],0.025,60890,DB00428,Streptozocin
,19009515,unbound AUC,"In diabetic rats, although the AUC of NFV was decreased after both intravenous (control: 1.75+/-0.08, diabetic: 1.36+/-0.17 microg h/ml) and intraduodenal (control: 1.69+/-0.25, diabetic: 1.19+/-0.39 microg h/ml) administrations, the unbound AUC was increased significantly (intravenous, control: 0.026+/-0.001, diabetic: 0.054+/-0.007 microg h/ml, intraduodenal, control: 0.025+/-0.004, diabetic: 0.048+/-0.016 microg h/ml).",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[h·μg] / [ml],0.048,60891,DB00428,Streptozocin
,19009515,unbound total clearance,"The unbound total clearance (control: 131.3+/-6.0, diabetic: 64.3+/-8.0 l/h/kg) and the unbound steady state distribution volume (control: 274.0+/-18.0, diabetic: 123.0+/-14.0 l/kg) were decreased significantly; therefore, greater pharmacological effects can be expected in diabetes mellitus.",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[l] / [h·kg],131.3,60892,DB00428,Streptozocin
,19009515,unbound total clearance,"The unbound total clearance (control: 131.3+/-6.0, diabetic: 64.3+/-8.0 l/h/kg) and the unbound steady state distribution volume (control: 274.0+/-18.0, diabetic: 123.0+/-14.0 l/kg) were decreased significantly; therefore, greater pharmacological effects can be expected in diabetes mellitus.",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[l] / [h·kg],64.3,60893,DB00428,Streptozocin
,19009515,unbound steady state distribution volume,"The unbound total clearance (control: 131.3+/-6.0, diabetic: 64.3+/-8.0 l/h/kg) and the unbound steady state distribution volume (control: 274.0+/-18.0, diabetic: 123.0+/-14.0 l/kg) were decreased significantly; therefore, greater pharmacological effects can be expected in diabetes mellitus.",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[l] / [kg],274.0,60894,DB00428,Streptozocin
,19009515,unbound steady state distribution volume,"The unbound total clearance (control: 131.3+/-6.0, diabetic: 64.3+/-8.0 l/h/kg) and the unbound steady state distribution volume (control: 274.0+/-18.0, diabetic: 123.0+/-14.0 l/kg) were decreased significantly; therefore, greater pharmacological effects can be expected in diabetes mellitus.",Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19009515/),[l] / [kg],123.0,60895,DB00428,Streptozocin
,30398126,Tmax,AZI (500 mg/kg) pretreatment significantly decreased AUC and increased Tmax to 8 h.,Effect of Aqueous Extract of Azadirachta indica Leaves on Pharmacokineics and Pharmacodynamics of Glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30398126/),h,8,63853,DB00428,Streptozocin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.15,64331,DB00428,Streptozocin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,4.01,64332,DB00428,Streptozocin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.02,64333,DB00428,Streptozocin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.21,64334,DB00428,Streptozocin
,9224812,elimination half-lives,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,57.17,64335,DB00428,Streptozocin
,9224812,elimination half-lives,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,26.02,64336,DB00428,Streptozocin
,9224812,Distribution volume,"Distribution volume was higher in diabetic than in normal rats (6.94 and 3.24 liter/kg, respectively; p = 0.049).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),[l] / [kg],6.94,64337,DB00428,Streptozocin
,9224812,Distribution volume,"Distribution volume was higher in diabetic than in normal rats (6.94 and 3.24 liter/kg, respectively; p = 0.049).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),[l] / [kg],3.24,64338,DB00428,Streptozocin
,1836304,production rates,"The plasma epinephrine production rates did not vary significantly between fetuses less than 135 and greater than 135 days' gestation (15.4 +/- 1.5 vs 13.9 +/- 2.0 ng/min, p greater than 0.5).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ng] / [min],15.4,67087,DB00428,Streptozocin
,1836304,production rates,"The plasma epinephrine production rates did not vary significantly between fetuses less than 135 and greater than 135 days' gestation (15.4 +/- 1.5 vs 13.9 +/- 2.0 ng/min, p greater than 0.5).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ng] / [min],13.9,67088,DB00428,Streptozocin
,1836304,metabolic clearance rate,"The fetal metabolic clearance rate of epinephrine at early gestations (less than 135 days) was similar to that of the fetus of the nondiabetic ewe (35.3 +/- 3.4 vs 28.0 +/- 4.3 ml/min/kg, p greater than 0.2).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],35.3,67089,DB00428,Streptozocin
,1836304,metabolic clearance rate,"The fetal metabolic clearance rate of epinephrine at early gestations (less than 135 days) was similar to that of the fetus of the nondiabetic ewe (35.3 +/- 3.4 vs 28.0 +/- 4.3 ml/min/kg, p greater than 0.2).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],28.0,67090,DB00428,Streptozocin
,1836304,metabolic clearance rate,"However, at later gestations (greater than 135 days) the fetus of the diabetic ewe did not have the increase in the metabolic clearance rate previously published for the control fetus (32.0 +/- 4.6 vs 133.7 +/- 41.7 ml/min/kg, p less than 0.05).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],32.0,67091,DB00428,Streptozocin
,1836304,metabolic clearance rate,"However, at later gestations (greater than 135 days) the fetus of the diabetic ewe did not have the increase in the metabolic clearance rate previously published for the control fetus (32.0 +/- 4.6 vs 133.7 +/- 41.7 ml/min/kg, p less than 0.05).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],133.7,67092,DB00428,Streptozocin
,27937081,Cmax,"When compared with the normal group, Cmax, t1/2 and AUC(0-t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[μg] / [l],17.35,67460,DB00428,Streptozocin
,27937081,t1/2,"When compared with the normal group, Cmax, t1/2 and AUC(0-t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[μg] / [l],34.41,67461,DB00428,Streptozocin
,27937081,t1/2,"When compared with the normal group, Cmax, t1/2 and AUC(0-t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),h,3.95,67462,DB00428,Streptozocin
,27937081,AUC(0-t),"When compared with the normal group, Cmax, t1/2 and AUC(0-t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[μg] / [h·l],151.21,67463,DB00428,Streptozocin
,27937081,AUC(0-t),"When compared with the normal group, Cmax, t1/2 and AUC(0-t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[μg] / [h·l],283.81,67464,DB00428,Streptozocin
,27937081,oral clearance,"In addition, oral clearance of berberine was significantly decreased in the model group (134.73 ± 32.15 vs 62.55 ± 16.34 L/h/kg).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[l] / [h·kg],134.73,67465,DB00428,Streptozocin
,27937081,oral clearance,"In addition, oral clearance of berberine was significantly decreased in the model group (134.73 ± 32.15 vs 62.55 ± 16.34 L/h/kg).",Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27937081/),[l] / [h·kg],62.55,67466,DB00428,Streptozocin
,16132341,relative bioavailabilities F(rel),"In both animal models significant concentrations of human insulin were detected, with relative bioavailabilities F(rel) of 2.8 up to 8.3%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),,2.8,78447,DB00428,Streptozocin
,16132341,relative bioavailabilities F(rel),"In both animal models significant concentrations of human insulin were detected, with relative bioavailabilities F(rel) of 2.8 up to 8.3%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,8.3,78448,DB00428,Streptozocin
,16132341,relative bioavailability F(rel),"The more hydrophobic, lactic acid grafted polyester were more effective at a threefold higher polymer concentration, increasing the relative bioavailability F(rel) of a 5 IU/kg dose from 2.8 to 5.7%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,2.8,78449,DB00428,Streptozocin
,16132341,relative bioavailability F(rel),"The more hydrophobic, lactic acid grafted polyester were more effective at a threefold higher polymer concentration, increasing the relative bioavailability F(rel) of a 5 IU/kg dose from 2.8 to 5.7%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,5.7,78450,DB00428,Streptozocin
,12859957,t(1/2),"This dose yielded glucose-lowering profiles with t(1/2) values at the range of 50-70h, turning catabolic STZ-rats into anabolic ones over a period of 2-3 days.",Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12859957/),h,50-70,83074,DB00428,Streptozocin
,30257345,IC50,Compound 1 was tested in the enzymatic assay showing an IC50 = 9.6 ± 0.5 μM and compound 2 showed about a 50% of inhibition of PTP-1B at 20 μM.,"Synthesis and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257345/),μM,9.6,87336,DB00428,Streptozocin
,31758056,zeta potential,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),m,-,90065,DB00428,Streptozocin
,31758056,zeta potential,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),m,18.2,90066,DB00428,Streptozocin
,31758056,entrapment efficiency,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),%,86.27,90067,DB00428,Streptozocin
,21319957,urine volume,"The urine volume of STZ mice was approximately 26 mL/day, 22 times that of normal mice.",Changes in the pharmacokinetics of digoxin in polyuria in streptozotocin-induced diabetic mice and lithium carbonate-treated mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21319957/),[ml] / [d],26,102540,DB00428,Streptozocin
,24203494,UAE,"Comparing control and 6 week STZ-treatment groups, UAE and inulin clearance increased from 25.7 ± 3.3 to 99.3 ± 13.7 μg/day, and from 421 ± 31 to 584 ± 78 μl/min.",Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μg] / [d],25.7,118274,DB00428,Streptozocin
,24203494,UAE,"Comparing control and 6 week STZ-treatment groups, UAE and inulin clearance increased from 25.7 ± 3.3 to 99.3 ± 13.7 μg/day, and from 421 ± 31 to 584 ± 78 μl/min.",Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μg] / [d],99.3,118275,DB00428,Streptozocin
,24203494,inulin clearance,"Comparing control and 6 week STZ-treatment groups, UAE and inulin clearance increased from 25.7 ± 3.3 to 99.3 ± 13.7 μg/day, and from 421 ± 31 to 584 ± 78 μl/min.",Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μl] / [min],421,118276,DB00428,Streptozocin
,24203494,inulin clearance,"Comparing control and 6 week STZ-treatment groups, UAE and inulin clearance increased from 25.7 ± 3.3 to 99.3 ± 13.7 μg/day, and from 421 ± 31 to 584 ± 78 μl/min.",Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μl] / [min],584,118277,DB00428,Streptozocin
,24203494,clearance,8C2 clearance increased from 121 ± 12.5 to 228 ± 61 μl/hr/kg (p < 0.01).,Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μl] / [h·kg],121,118278,DB00428,Streptozocin
,24203494,clearance,8C2 clearance increased from 121 ± 12.5 to 228 ± 61 μl/hr/kg (p < 0.01).,Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203494/),[μl] / [h·kg],228,118279,DB00428,Streptozocin
,8104128,Total clearance,Total clearance of zenarestat significantly increased in male chronic diabetic rats (15.3-->42.2 ml/hr/kg).,"Pharmacokinetics of zenarestat, an aldose reductase inhibitor, in male and female diabetic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104128/),[ml] / [h·kg],15.3,132832,DB00428,Streptozocin
,8104128,Total clearance,Total clearance of zenarestat significantly increased in male chronic diabetic rats (15.3-->42.2 ml/hr/kg).,"Pharmacokinetics of zenarestat, an aldose reductase inhibitor, in male and female diabetic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104128/),[ml] / [h·kg],42.2,132833,DB00428,Streptozocin
,14967537,area under the curve (AUC),"The pharmacokinetics of metformin from the mucoadhesive dosage forms indicated that for metformin alone, the area under the curve (AUC) values were 125.6 and 135.6 mgh/ml at 200 and 400 mg/kg BW, respectively.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),[mgh] / [ml],125.6,134367,DB00428,Streptozocin
,14967537,area under the curve (AUC),"The pharmacokinetics of metformin from the mucoadhesive dosage forms indicated that for metformin alone, the area under the curve (AUC) values were 125.6 and 135.6 mgh/ml at 200 and 400 mg/kg BW, respectively.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),[mgh] / [ml],135.6,134368,DB00428,Streptozocin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,102.4,134369,DB00428,Streptozocin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,150.2,134370,DB00428,Streptozocin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,59.9,134371,DB00428,Streptozocin
,14967537,AUCs,"For the mucoadhesive products using the same dose levels, the AUCs were modified to 102.4 and 150.2 in detarium gum and 59.9 and 80.4 in NaCMC.",Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14967537/),,80.4,134372,DB00428,Streptozocin
,30721709,oral bioavailability,"Finally, according to pharmacokinetic analyses, insulin-loaded DC-LIPs show a significant hypoglycemic effect with an oral bioavailability of 16.1% in rats with type I diabetes.",A Delivery System for Oral Administration of Proteins/Peptides Through Bile Acid Transport Channels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721709/),%,16.1,139019,DB00428,Streptozocin
,23058052,half-life,In SD rats its half-life was prolonged to 27.12 ± 5.75 h which was 17.61-fold longer than that of the natural exendin-4 for which the half-life was only 1.54 ± 0.47 h.,A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058052/),h,27.12,139183,DB00428,Streptozocin
,23058052,half-life,In SD rats its half-life was prolonged to 27.12 ± 5.75 h which was 17.61-fold longer than that of the natural exendin-4 for which the half-life was only 1.54 ± 0.47 h.,A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058052/),h,1.54,139184,DB00428,Streptozocin
,20655382,drop,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),nm,161.7,151112,DB00428,Streptozocin
,20655382,PDI,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),,0.447,151113,DB00428,Streptozocin
,20655382,entrapment,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),%,∼85,151114,DB00428,Streptozocin
,19859566,total body clearance,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),[l] / [hr],0.457,165858,DB00428,Streptozocin
,19859566,total body clearance,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),[l] / [hr],0.201,165859,DB00428,Streptozocin
,19859566,biological half-life,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),h,9.32,165860,DB00428,Streptozocin
,19859566,biological half-life,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),h,22.56,165861,DB00428,Streptozocin
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],11.3,176452,DB00428,Streptozocin
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],13.6,176453,DB00428,Streptozocin
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],8.06,176454,DB00428,Streptozocin
,16312011,Clnr,"As expected, after intravenous administration, the Clnr values of diclofenac were significantly slower in rat models of DMIA (11.3 versus 13.6 ml/min/kg) and DMIS (8.06 versus 15.2 ml/min/kg) than those in control rats.",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[ml] / [kg·min],15.2,176455,DB00428,Streptozocin
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],435,176456,DB00428,Streptozocin
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],367,176457,DB00428,Streptozocin
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],540,176458,DB00428,Streptozocin
,16312011,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"As a result, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values were significantly greater in rat models of DMIA (435 versus 367 microg min/ml) and DMIS (540 versus 329 microg min/ml).",Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16312011/),[min·μg] / [ml],329,176459,DB00428,Streptozocin
,15950411,t(1/2),It was observed that t(1/2) values varied between 0.53 and 1.31h.,A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950411/),h,0.53 and 1.31,177406,DB00428,Streptozocin
,10600267,area under the serum DOX time-concentration curve (AUC(0-24 h)),In STZ diabetic rats the area under the serum DOX time-concentration curve (AUC(0-24 h)) increased (13.35+/-1.33 compared with 7.13+/-0.71 microg h(-1) ml(-1); P<0.0001) and plasma and renal DOX clearance decreased.,Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [h·ml],13.35,183088,DB00428,Streptozocin
,10600267,area under the serum DOX time-concentration curve (AUC(0-24 h)),In STZ diabetic rats the area under the serum DOX time-concentration curve (AUC(0-24 h)) increased (13.35+/-1.33 compared with 7.13+/-0.71 microg h(-1) ml(-1); P<0.0001) and plasma and renal DOX clearance decreased.,Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [h·ml],7.13,183089,DB00428,Streptozocin
,10600267,accumulation,"The DOX accumulation in STZ-induced diabetic rat heart (12.7+/-1.2 microg g(-1)) was increased (P<0.05) compared with non-diabetic hearts (11.0+/-0.9 microg/g), 24 h after DOX administration.",Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [g],12.7,183090,DB00428,Streptozocin
,10600267,accumulation,"The DOX accumulation in STZ-induced diabetic rat heart (12.7+/-1.2 microg g(-1)) was increased (P<0.05) compared with non-diabetic hearts (11.0+/-0.9 microg/g), 24 h after DOX administration.",Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [g],11.0,183091,DB00428,Streptozocin
,2954633,half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,40.76,186414,DB00428,Streptozocin
,2954633,terminal half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,0.52,186415,DB00428,Streptozocin
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],52.6,193748,DB00428,Streptozocin
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],67.4,193749,DB00428,Streptozocin
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],50.2,193750,DB00428,Streptozocin
,18261364,CLNR,"After intravenous administration of omeprazole, the CLNR of the drug was significantly faster in DMIA (52.6 versus 67.4 mL/min/kg) and DMIS (50.2 versus 73.0 mL/min/kg) rats than the respective controls.",Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261364/),[ml] / [kg·min],73.0,193751,DB00428,Streptozocin
,1458714,total area under the concentration versus time curves (AUC),The mean total area under the concentration versus time curves (AUC) was 183 +/- 31 (SE) mM min in the peritoneal cavity (5 courses) and 5.3 +/- 1.1 (SE) mM min in plasma (6 courses).,Pharmacokinetic study of intraperitoneal streptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458714/),mM·min,183,226070,DB00428,Streptozocin
,1458714,total area under the concentration versus time curves (AUC),The mean total area under the concentration versus time curves (AUC) was 183 +/- 31 (SE) mM min in the peritoneal cavity (5 courses) and 5.3 +/- 1.1 (SE) mM min in plasma (6 courses).,Pharmacokinetic study of intraperitoneal streptozotocin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458714/),mM·min,5.3,226071,DB00428,Streptozocin
,1458714,peritoneal to plasma AUC ratio,The mean peritoneal to plasma AUC ratio was 64 +/- 23 (5 courses).,Pharmacokinetic study of intraperitoneal streptozotocin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458714/),,64,226072,DB00428,Streptozocin
,1458714,peak streptozotocin concentrations,"The mean peak streptozotocin concentrations in the peritoneal cavity (5 courses) and plasma (6 courses) were 1.9 +/- 0.4 mM and 0.03 +/- 0.01 mM, respectively.",Pharmacokinetic study of intraperitoneal streptozotocin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458714/),mM,1.9,226073,DB00428,Streptozocin
,1458714,peak streptozotocin concentrations,"The mean peak streptozotocin concentrations in the peritoneal cavity (5 courses) and plasma (6 courses) were 1.9 +/- 0.4 mM and 0.03 +/- 0.01 mM, respectively.",Pharmacokinetic study of intraperitoneal streptozotocin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458714/),mM,0.03,226074,DB00428,Streptozocin
,33262587,Half-life,Half-life of the formulation was found to be 13.947 ± 0.596 h.,Sesamol-Loaded PLGA Nanosuspension for Accelerating Wound Healing in Diabetic Foot Ulcer in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33262587/),h,13.947,234307,DB00428,Streptozocin
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],77.3,234749,DB00428,Streptozocin
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],45.9,234750,DB00428,Streptozocin
,24346850,V max,"Moreover, SMN-treated animals showed a significant (P < 0.05) reduction of V max (59.4 ± 6.1 pM/min/mg).",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],59.4,234751,DB00428,Streptozocin
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],6.98,234752,DB00428,Streptozocin
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],4.35,234753,DB00428,Streptozocin
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.52,234754,DB00428,Streptozocin
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.33,234755,DB00428,Streptozocin
,6451687,first-order reaction constant,"Furthermore, the first-order reaction constant derived in analyzing the bioassay data (0.009 min-1) was in close agreement with the half-life of streptozocin (1 hr) reported previously.",Preliminary model for streptozocin metabolism in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6451687/),1/[min],0.009,239571,DB00428,Streptozocin
,6451687,half-life,"Furthermore, the first-order reaction constant derived in analyzing the bioassay data (0.009 min-1) was in close agreement with the half-life of streptozocin (1 hr) reported previously.",Preliminary model for streptozocin metabolism in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6451687/),h,1,239572,DB00428,Streptozocin
,29783787,flow rate,"Following liquid⁻liquid extraction by tert-butyl methyl ether, chromatographic separation of canagliflozin and its metabolites were performed on a Waters XBridge BEH C18 column (100 × 2.1 mm, 2.5 μm) using 0.1% acetonitrile⁻formic acid (75:15, v/v) as the mobile phase at a flow rate of 0.7 mL/min.",Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29783787/),[ml] / [min],0.7,242232,DB00428,Streptozocin
,1358579,CLbile,"The mean CLbile value of CPZ in the STZ-treated rats was 1.0 ml/min higher than that of the control rats, whereas the mean CLbile value of CED was almost the same as that of the control rats.",Comparative pharmacokinetics of cefoperazone and cephradine in untreated streptozotocin diabetic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358579/),[ml] / [min],1.0,272721,DB00428,Streptozocin
